Melanotan I Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Related MC1R-selective analog afamelanotide is FDA/EMA-approved for a specific photoprotection indication (erythropoietic protoporphyria); Melanotan I itself has more limited independent human trial data.

Animal evidence: Rodent melanogenesis studies support the mechanism.

Introduction & Mechanism of Action

Melanocortin-1 receptor agonist studied for melanogenesis and photoprotection research.

Selective MC1R agonist stimulating melanin production in skin; more receptor-selective than Melanotan II, which also engages other melanocortin receptors linked to libido and appetite effects.

Receptors/targets: Melanocortin-1 receptor (MC1R)

Areas of Research Interest

• Pigmentation research
• Photoprotection studies

Benefits Reported in Research

• Pigmentation research
• Photoprotection studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 0.25–1 mg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 4–8 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on Melanotan I reports administration at 0.25–1 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 10 mg vial with 2 mL bacteriostatic water, yielding a concentration of 5.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Nausea
• Flushing
• Injection-site reaction
• Skin darkening (intended effect, but can be uneven)

Contraindications

• History of melanoma or atypical nevi
• Pregnancy

Drug interactions

• Not well characterized in controlled human trials

Safety

• Nausea during dose escalation
• Unregulated compounded supply carries purity/dosing variability

Should not be conflated with the FDA/EMA-approved afamelanotide implant; compounded versions carry distinct safety-data gaps.

Expected Results & Comparison

Melanotan I is more receptor-selective (MC1R only) than Melanotan II, which also engages MC3R/MC4R and is associated with libido and appetite effects. This makes Melanotan I's side-effect profile narrower in principle, though independent human comparative data is limited for both.

References

Continue